

Welcome to the AMR Global Health Academy Monthly Brief



Edition 1 | January/February 2026

The AMR Global Health Academy supports global health professionals and antimicrobial stewards—particularly in low- and middle-income countries—through a free, practice-oriented educational curriculum designed to strengthen antimicrobial stewardship, diagnostics, and surveillance. Each month, this brief curates key signals from the AMR field and links them to learning resources that support real-world decision-making.

As we begin 2026, we would like to thank those who completed the end-of-year survey. Your feedback has helped shape refinements to this brief for the coming year.

In 2025, the AMR Global Health Academy Monthly Brief reached over **11,000 colleagues worldwide each month**, representing **more than 180 countries**. Approximately 40% of recipients opened the brief, and one in three readers clicked through to explore learning resources and related content. Readership was highest in India, the Philippines, Brazil, Nigeria, Cameroon, and Indonesia—reflecting the global reach and relevance of the Academy’s work. We look forward to continuing to support AMR stewards in 2026 by sharing timely insights, practical learning opportunities, and curated resources that translate evidence into action.

What to Expect in 2026

Based on feedback from our end-of-year survey, we are refining the AMR Global Health Academy Monthly Brief in 2026 to make it more focused, practical, and easier to act on. While readers value staying informed about developments in the AMR field, many asked for clearer guidance on **what matters most** and **where to focus their time**.

This year, each monthly brief will:

- Highlight one primary learning pathway each month
- Interpret key developments and what they mean for practice
- Share curated news, opportunities, and events in a streamlined format

Our goal is to help AMR stewards move more easily from awareness to action, while keeping the brief concise, relevant, and globally applicable.

The Monthly Signal *From Innovation to Stewardship*

As 2026 begins, antimicrobial resistance remains a growing global threat, even as new tools, therapies, and engagement efforts continue to emerge. For AMR stewards, the challenge is no longer a lack of evidence, but how effectively diagnostics, treatment decisions, and stewardship principles are translated into routine practice across diverse settings. This first brief of the year orients learners to practical resources that support informed action—not just awareness—as the AMR community moves from innovation to stewardship.

GHIG/GHCPD uses briefs as short, decision-oriented communications rather than traditional newsletters.

Featured Learning Pathway — START HERE

The AMR Global Health Academy offers a structured, practice-oriented learning pathway for clinicians, laboratorians, and public health professionals working to strengthen antimicrobial stewardship across diverse settings.

The AMR Academy course map provides a clear overview of available learning opportunities, including:

- Problem-solving case studies focused on real-world stewardship decisions
- Syndromic modules linking diagnostics, antimicrobial use, and patient outcomes
- Multilingual learning materials (English, French, Portuguese, Spanish)

If you take one action this month, start here.

 [Explore the AMR Academy overview and course map](#)

What This Means for AMR Stewards — PRACTICE INSIGHT *New oral therapies for gonorrhea: promise and responsibility*

The recent approval of new oral therapies for gonorrhea (gepotidacin and zoliflodacin) represents an important advance at a time of rising resistance to existing treatments. These developments expand therapeutic options, but they also underscore the importance of strong antimicrobial stewardship to preserve the effectiveness of new agents.

Why this matters:

- Provides new options for treating drug-resistant *Neisseria gonorrhoeae*
- Reinforces the need for diagnostic confirmation and surveillance
- Highlights the risk of rapid resistance emergence without stewardship guardrails

While new oral therapies expand treatment options, their responsible use depends on diagnostic confirmation, timely laboratory reporting, and alignment between laboratory and clinical teams—highlighting the central role of diagnostics in stewardship. In many settings, this decision hinges on whether diagnostic confirmation is available at the point-of-care or requires referral testing, with implications for turnaround time and empiric treatment choices.

For **laboratory managers**, this highlights the importance of reporting workflows and communication with clinical teams when new therapies are introduced.

Stewardship cue:

New treatment options strengthen care only when paired with **diagnostic confirmation, timely laboratory reporting, informed prescribing, and follow-up.**

Selected resources:

- Gepotidacin — [FDA approval](#) and [Phase 3 study](#)
- Zoliflodacin — [FDA approval](#) and [Phase 3 study](#)
- [Lancet commentary on gepotidacin](#)
- [Lancet commentary on zoliflodacin](#)

Community & Opportunities

In case you missed it:

- [Youth Manifesto on AMR](#) (*Nature Communications*): A call to action highlighting how equitable engagement of youth can strengthen AMR research, policy, and practice.
- [AMR at Davos](#): Global leaders convened at a Frontiers Science House discussion to underscore the urgency of prioritizing AMR as a global health and development challenge.
- [CARB-X resources](#): Open-access recordings, publications, and educational bootcamps supporting innovation across the AMR pipeline.



Don't miss:

- [AMR 2026 Summit](#) — Sydney, Australia | 18–20 February 2026
- [10th AMR Conference](#) — Basel, Switzerland | 3–4 March 2026
- [Gordon Research Conference: Antibacterials of Tomorrow](#) — Tuscany, Italy | 8–13 March 2026
- [ESCMID Global 2026](#) — Munich, Germany | 17–21 April 2026
- [Global AMR Innovators Conference \(GAMRIC\)](#) — Lisbon, Portugal | 22–24 September 2026
- [ICARe Course on Antibiotics and Resistance](#) — Annecy, France | 10–18 October 2026
- [International AIDS Society \(IAS\) Conference](#) — Brazil | 26–31 July 2026.

Opportunities

- [WHO](#) — Modelers to support adaptation of empiric antibiotic guidance. Deadline: 16 February
- [Horizon Europe](#) — Calls on new antimicrobials, point-of-care diagnostics, and post-infection conditions
- [GARDP](#) — Open positions in clinical science, R&D partnerships, and medical sciences

What's Next

In 2026, our focus is on translating AMR guidance into practice through case-based problem-solving vignettes that reflect the **diagnostic, prescribing, and stewardship decisions** frontline teams make every day. More to come.

The AMR Academy Monthly Brief is a free, grant-supported educational communication that maximizes the impact of funded learning activities and strengthens the case for continued investment.

The AMR Global Health Academy is supported by an independent educational grant from bioMérieux. The content and views expressed are those of the authors.